Skip to content

Beam Therapeutics Inc.

BEAM

CIK 0001745999

← back to feed
Revenue (TTM)
$57.37M
+120.0% YoY Q1 Apr 2026
Net Income (TTM)
−$418.61M
+78.8% YoY Q1 Apr 2026
EPS Diluted (TTM)
−$4.24
+82.3% YoY Q1 Apr 2026
Gross Margin
—
Q1 Apr 2026
Operating Margin
-825.3%
Q1 Apr 2026
Net Margin
-729.6%
Q1 Apr 2026
Free Cash Flow (TTM)
−$455.71M
Q1 Apr 2026
Cash
$288.29M
Q1 Apr 2026
Total Debt
$100.19M
Q1 Apr 2026
Shares Outstanding
102.88M sh
Q1 Apr 2026

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings